Recruiting

Testing a new skin medication for moderate to severe eczema

Plain-English translation of NCT07277660 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Read our Atopic Dermatitis research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a research study testing a new medication called to see if it can help adults with moderate to severe atopic dermatitis (eczema). Researchers want to find the right dose of this medication that works best while being safe. About 160 adults will participate, and some will receive the medication at different dose levels while others receive a placebo (a dummy pill with no active ingredient) to compare results.

Many people with moderate to severe eczema don't respond well to creams and lotions alone, and they need stronger treatments. This study is trying to find out whether this new medication could be a safe and effective option for people whose eczema isn't controlled by topical treatments.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have had atopic dermatitis (eczema) for at least one year
your eczema is moderate to severe and affects at least 10% of your body surface area
your eczema causes significant itching that you rate as 4 or higher on a pain scale
your eczema has not responded well to creams and lotions, or you cannot safely use topical treatments

You likely don't qualify if…

you have other skin conditions (like psoriasis, scabies, or certain types of dermatitis) that could interfere with the study
you have inflammatory bowel disease or a family history of it
you have had serious or life-threatening infections in the past 6 months
you have previously been treated with galvokimig or had safety problems with similar eczema medications (dupilumab, tralokinumab, or lebrikizumab)
you are currently taking other systemic eczema medications, as these must be stopped at least 4 weeks before the study begins

What participation looks like

If you join this study, you will receive either the medication or a placebo (at different dose levels if you get the medication) and take it during an initial 16-week treatment period. After 16 weeks, you may continue on the same dose or have it adjusted based on how you're responding. Throughout the study, you'll have regular visits to check how your skin is improving, measure your symptoms, and monitor for any side effects. The study will help researchers understand the best dose of this new medication and whether it safely improves atopic dermatitis.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(62 sites)

United States

Atd002 52021, Oceanside, California

Atd002 52008, Santa Monica, California

Atd002 52013, Boca Raton, Florida

Atd002 52007, Coral Gables, Florida

Atd002 52003, Miami, Florida